Furthermore, in the subset of patients with bone metastases, higher bone sialoprotein levels are related to a shorter time to develop bone metastases in patients with prostate cancer, osteopontin may be of use in assessing treatment response post chemotherapy in patients with castration-resistant prostate cancer [8]. This evidence concerns the gene SPP1 and Familial prostate cancer.